Moreover, if positive, the TETON data in idiopathic pulmonary fibrosis which is expected soon ... many years in the clinic and in patients' hands and in essentially about 24 months or so to ...

The outcomes of patients with idiopathic pulmonary fibrosis (IPF) remain unknown. Alongside the global adoption of antifibrotic therapies, there is currently relentless research for biomarkers and ...

Researchers at Tulane University have identified a potential new way to treat idiopathic pulmonary fibrosis (IPF), a deadly ...

Roughly one in five (21 percent) of idiopathic pulmonary fibrosis (IPF) deaths might be related to occupational exposures, according to research published in the March 6 issue of the U.S. Centers ...

A promising new treatment approach for idiopathic pulmonary fibrosis (IPF), a fatal and currently untreatable lung disease affecting over 3 million people globally, has been identified by Tulane ...

Novotech, a globally recognized full-service clinical research organization (CRO) and scientific advisory partner for biotech and small- to mid-sized pharmaceutical companies seeking to advance ...

SYDNEY, April 21, 2025--(BUSINESS WIRE)--Novotech, a globally recognized full-service clinical research organization (CRO) and scientific advisory partner for biotech and small- to mid-sized ...

Advancing IPF Clinical Research: A Global Perspective Idiopathic Pulmonary Fibrosis (IPF) is a chronic, progressive lung disease characterized by the scarring of lung tissue and a steady decline in ...

Researchers have identified a potential new way to treat idiopathic pulmonary fibrosis (IPF), a deadly and currently incurable lung disease that affects more than 3 million people worldwide.